Literature DB >> 19050065

Treatment of chronic myeloid leukemia in blast crisis.

R Hehlmann, S Saussele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19050065     DOI： 10.3324/haematol.2008.001214

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

1.  Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Authors:  Hagop M Kantarjian; Neil P Shah; Jorge E Cortes; Michele Baccarani; Mohan B Agarwal; María Soledad Undurraga; Jianxiang Wang; Juan Julio Kassack Ipiña; Dong-Wook Kim; Michinori Ogura; Carolina Pavlovsky; Christian Junghanss; Jorge H Milone; Franck E Nicolini; Tadeusz Robak; Jan Van Droogenbroeck; Edo Vellenga; M Brigid Bradley-Garelik; Chao Zhu; Andreas Hochhaus
Journal:  Blood       Date:  2011-12-09       Impact factor: 22.113

Review 2.  Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Authors:  Tomas Radivoyevitch; Lynn Hlatky; Julian Landaw; Rainer K Sachs
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

3.  Novel Cytogenetic Aberrations in a Patient of Chronic Myeloid Leukemia with Blast Crisis.

Authors:  Bhoumik Shah; Smeeta Gajendra; Ritu Gupta; Atul Sharma
Journal:  J Clin Diagn Res       Date:  2015-05-01

4.  Myeloid sarcoma as the presenting symptom of chronic myelogenous leukemia blast crisis.

Authors:  Rebecca A Levy; Mabel A Mardones; Micah M Burch; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-07

5.  [Modern therapy of chronic myeloid leukemia: an example for paradigma shift in hemato-oncology].

Authors:  A A Leitner; R Hehlmann
Journal:  Internist (Berl)       Date:  2011-02       Impact factor: 0.743

6.  Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Authors:  Wolfgang R Sperr; Thomas Pfeiffer; Gregor Hoermann; Susanne Herndlhofer; Christian Sillaber; Christine Mannhalter; Michael Kundi; Peter Valent
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

7.  A multicellular basis for the origination of blast crisis in chronic myeloid leukemia.

Authors:  Rainer K Sachs; Kerstin Johnsson; Philip Hahnfeldt; Janet Luo; Allen Chen; Lynn Hlatky
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

8.  Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.

Authors:  Zimu Gong; L Jeffrey Medeiros; Jorge E Cortes; Zi Chen; Lan Zheng; Yan Li; Shi Bai; Pei Lin; Roberto N Miranda; Jeffrey L Jorgensen; Timothy J McDonnell; Wei Wang; Hagop M Kantarjian; Shimin Hu
Journal:  Blood Adv       Date:  2017-12-08

9.  Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.

Authors:  Daniela Bossi; Francesca Carlomagno; Isabella Pallavicini; Giancarlo Pruneri; Maurizio Trubia; Paola Rafaniello Raviele; Alessandra Marinelli; Suresh Anaganti; Maria Christina Cox; Giuseppe Viale; Massimo Santoro; Pier Paolo Di Fiore; Saverio Minucci
Journal:  Mol Oncol       Date:  2013-11-19       Impact factor: 6.603

10.  BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells.

Authors:  Norihiro Ueda; Rong Zhang; Minako Tatsumi; Tian-Yi Liu; Shuichi Kitayama; Yutaka Yasui; Shiori Sugai; Tatsuaki Iwama; Satoru Senju; Seiji Okada; Tetsuya Nakatsura; Kiyotaka Kuzushima; Hitoshi Kiyoi; Tomoki Naoe; Shin Kaneko; Yasushi Uemura
Journal:  Cell Mol Immunol       Date:  2016-05-15       Impact factor: 11.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.